Continuous tamoxifen treatment prevents grow-back of residual Pax7-expressing satellite cells. (A) Quantification of Pax7-expressing nuclei in Pax7fl/CreERT2 mice induced with tamoxifen before and after acute injury; n = 3, **P < 0.01. (B) Quantification of Pax7-expressing nuclei in Pax7fl/CreERT2 mice with continuous tamoxifen application before and after acute injury; n = 3, **P < 0.01. (C) Pax7 expression is lost after tamoxifen-induced excision in Pax7fl/CreERT2 mice (IP injection) but reoccurs after acute injury, Pax7 immunostaining is shown in green, and nuclei are counterstained with DAPI (in blue). Staining for α7-integrin is shown in red, and nuclei are counterstained with DAPI (in blue). (D) Pax7 deletion is only maintained when tamoxifen is continuously administered during regeneration of CTX-injured muscles, Pax7 immunostaining is shown in green, and nuclei are counterstained with DAPI (in blue). Staining for α7-integrin is shown in red, and nuclei are counterstained with DAPI (in blue). (E) Quantification of numbers of satellite cells (marked by expression of α7-integrin) in Pax7fl/CreERT2 mice induced with tamoxifen before and after acute injury; n = 3. (F) Quantification of numbers of satellite cells (marked by expression of α7-integrin) in Pax7fl/CreERT2 mice with continuous tamoxifen application before and after acute injury; n = 3, **P < 0.01. (Scale bar: 50 µm.)